Danish pharmaceutical company Novo Nordisk has agreed to sell its popular Wegovy and Ozempic drugs through U.S. telehealth provider Hims & Hers’ platform, settling a legal dispute that arose last month.
Under the terms of the agreement, Hims & Hers will provide US consumers with access to FDA-approved Ozempic injection and Wegovy tablets and injections at the same affordable self-pay prices as other telehealth platforms.
Mike Doustdar, President and CEO of Novo Nordisk, told investors, “This agreement with Hims & Hers is a meaningful win for patients in the United States. By expanding access through leading telehealth providers and digital care platforms, we are helping to connect more people with our FDA-approved medicines, which have been evaluated for safety and efficacy.”
Andrew Dudum, co-founder and CEO of Hims & Hers, stated, “I’m excited to have a great partner in Novo Nordisk as we work to create a new model that works for everyday people. This collaboration reflects what’s possible globally when drugmakers, biotech companies, and diagnostic leaders partner with consumer platforms to support scaled distribution of their latest medical innovations.”
Doustdar mentioned that the Wegovy pill has been prescribed over 600,000 times in the two months since its launch, with telehealth partnerships helping to boost its adoption.
The deal marks a sharp change from February, when Novo filed a lawsuit against Hims over a $49 compounded alternative to its Wegovy weight-loss medication.
Under the terms of the agreement, Hims & Hers will no longer advertise compounded GLP-1 offerings on its platform or in its marketing, and existing patients will have the opportunity to transition to FDA-approved alternatives when clinically appropriate in consultation with a healthcare professional.
Hims & Hers shares surged 50% following the announcement.
By CEO NA Editorial Staff
